March 11, 2014
The Pharmaceuticals and Medical Devices Agency (PMDA) raised caution regarding the risk of teratogenicity due to Chugai Pharmaceutical’s keratosis treatment Tigason (etretinate) on March 3, after the second case of congenital abnormality was reported in Japan following the administration of...read more